Hemostasis Diagnostics Market by Product, Test Type, End Use

Description

List of Tables

[180 Pages Report] The Hemostasis Diagnostics Market size was estimated at USD 579.32 million in 2023 and expected to reach USD 620.10 million in 2024, at a CAGR 8.04% to reach USD 995.77 million by 2030.

Global Hemostasis Diagnostics Market

KEY MARKET STATISTICS
Base Year [2023]	USD 579.32 million
Estimated Year [2024]	USD 620.10 million
Forecast Year [2030]	USD 995.77 million
CAGR (%)	8.04%

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hemostasis Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hemostasis Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hemostasis Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ARUP Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, DiaPharma Group, Inc., F. Hoffmann-La Roche Ltd., Grifols, S.A., Haemonetics Corporation, Helena Laboratories Corporation, HemoSonics, LLC, HORIBA Group, Laboratory Corporation of America Holdings, Medtronic PLC, Merck & Co., Inc., Randox Laboratories Ltd., Siemens AG, Stago Group, Sysmex America, Inc., Sysmex Europe SE, Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, Thermo Fisher Scientific Inc., and Werfen, S.A..

Market Segmentation & Coverage

This research report categorizes the Hemostasis Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Consumables
- Laboratory Analyzers
- Point-of-Care Testing Systems
Test Type
- Activated Clotting Time
- Activated Partial Thromboplastin Time
- D Dimer Test
- Fibrinogen Test
- Platelet Aggregation Test
- Prothrombin Time (PT) Test
End Use
- Home Care Setting
- Hospitals/Clinics
- Independent Diagnostic Laboratories
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Hemostasis Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hemostasis Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Hemostasis Diagnostics Market?

4. What is the market share of the leading vendors in the Hemostasis Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Hemostasis Diagnostics Market?

Product Code: MRR-DD0700E81E5A

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Hemostasis Diagnostics Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increase in incidences of hemostasis disorders worlwide
  - 5.1.1.2. Inclination toward point-of-care testing solutions
  - 5.1.1.3. Growing awareness of hemostasis disorders and emphasis on early diagnosis
- 5.1.2. Restraints
  - 5.1.2.1. High cost of diagnosis and incidences of product recall
- 5.1.3. Opportunities
  - 5.1.3.1. Utilization of personalized medicine approach to deliver tailored treatments
  - 5.1.3.2. Advancements in diagnostic methods for hemostasis
- 5.1.4. Challenges
  - 5.1.4.1. Complex testing methods for hemostasis diagnosis
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Hemostasis Diagnostics Market, by Product

6.1. Introduction
6.2. Consumables
6.3. Laboratory Analyzers
6.4. Point-of-Care Testing Systems

7. Hemostasis Diagnostics Market, by Test Type

7.1. Introduction
7.2. Activated Clotting Time
7.3. Activated Partial Thromboplastin Time
7.4. D Dimer Test
7.5. Fibrinogen Test
7.6. Platelet Aggregation Test
7.7. Prothrombin Time (PT) Test

8. Hemostasis Diagnostics Market, by End Use

8.1. Introduction
8.2. Home Care Setting
8.3. Hospitals/Clinics
8.4. Independent Diagnostic Laboratories

9. Americas Hemostasis Diagnostics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Hemostasis Diagnostics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Hemostasis Diagnostics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Abbott Laboratories
- 13.1.2. ARUP Laboratories
- 13.1.3. Becton, Dickinson and Company
- 13.1.4. Bio-Rad Laboratories, Inc.
- 13.1.5. bioMerieux SA
- 13.1.6. Danaher Corporation
- 13.1.7. DiaPharma Group, Inc.
- 13.1.8. F. Hoffmann-La Roche Ltd.
- 13.1.9. Grifols, S.A.
- 13.1.10. Haemonetics Corporation
- 13.1.11. Helena Laboratories Corporation
- 13.1.12. HemoSonics, LLC
- 13.1.13. HORIBA Group
- 13.1.14. Laboratory Corporation of America Holdings
- 13.1.15. Medtronic PLC
- 13.1.16. Merck & Co., Inc.
- 13.1.17. Randox Laboratories Ltd.
- 13.1.18. Siemens AG
- 13.1.19. Stago Group
- 13.1.20. Sysmex America, Inc.
- 13.1.21. Sysmex Europe SE
- 13.1.22. Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH
- 13.1.23. Thermo Fisher Scientific Inc.
- 13.1.24. Werfen, S.A.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing